Amit Khaneja
Clinical Neurophysiology · Yonkers, NYNPI 1922261486
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,909 of the $2,539 with a category attached, or 75.2%. 19 manufacturers reported payments, led by Medtronic at 34.3% of the total. Reporting peaked in 2022 at $832 and has fallen 51.5% since, to $403 in 2025.
Across 82 payments — averaging $30.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$872
- SK Life Science, Inc.$257
- UCB, Inc.$226
- Octapharma USA, Inc.$226
- AstraZeneca$172
- Neurocrine Biosciences, Inc.$115
- plus $669 from 13 others
What the payments were for
- Travel & lodging$63025%
- Food & beverage$1,90975%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $872 |
| SK Life Science, Inc. | 12 | $257 |
| UCB, Inc. | 12 | $226 |
| Octapharma USA, Inc. | 8 | $226 |
| AstraZeneca(2 entities) | 5 | $172 |
| Neurocrine Biosciences, Inc. | 4 | $115 |
| AbbVie | 4 | $111 |
| Eisai Inc. | 5 | $103 |
| Argenx US, Inc. | 3 | $78 |
| Pfizer | 3 | $65 |
| Johnson & Johnson(2 entities) | 2 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Biogen | 2 | $36 |
| Ceribell, Inc. | 1 | $34 |
| Invivyd Inc | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Neurelis, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
How this compares
$2,539 in reported general payments places this provider in the 70th percentile of 35 clinical neurophysiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 85 | $4,551 |
| Lacosamide | 23 | $4,157 |
| Divalproex Sodium | 13 | $3,457 |
| Carbamazepine | 19 | $1,536 |
| RivastigmineRivastigmine Tartrate | 12 | $781 |
| Lamotrigine | 21 | $654 |
| Zonisamide | 11 | $565 |
| Phenobarbital | 23 | $482 |
| Phenytoin Sodium Extended | 12 | $376 |
| Gabapentin | 27 | $255 |
| Topiramate | 20 | $173 |
| Donepezil Hcl | 12 | $56 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in Yonkers
- Alcibiades RodriguezNew York$714K
- Farhad Kadkhodaei ElyaderaniBronx$156K
- Jessica Robinson-PappNew York$28K
- Mohini GurmeWest Nyack$13K
- Cecily AntoHauppauge$11K
- Itzhak HaimovicGreat Neck$7K
- Madeline FieldsNew York$5K
- Agnieszka KokoszkaNew York$5K
- Justin SilversteinHauppauge$3K
- Simona ProteasaGreat Neck$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.